Navigation Links
Biopure Receives Notices About Nasdaq Listing Compliance
Date:3/31/2009

CAMBRIDGE, Mass., March 31 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has received several notices from The Nasdaq Stock Market. By letter dated March 24, 2009, Nasdaq advised that, as the company had not yet filed its Form 10-Q for the fiscal quarter ended January 31, 2009, it was out of compliance with the Nasdaq Marketplace Rules. The company filed the report and received a letter dated March 26, 2009, stating that the matter was closed.

NASDAQ also notified the company that it has suspended enforcement of its minimum bid price and market value requirements for continued listing, thereby extending the company's time in which to regain compliance. Enforcement of these rules is scheduled to resume on July 20, 2009. The company estimates, that it now has until September 12, 2009, to regain compliance with the $1.00 minimum bid price requirement. If at any time before that date the bid price of the company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the company should be provided written notification that it complies with the Marketplace Rules.

Biopure Corporation

Biopure Corporation develop and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the company announced that it had suspended manufacturing and terminated most of its work force for financial reasons. The company may not be able to continue as a going concern. Using its limited resources, the company is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, is the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission. The product, is indicated for the treatment of anemia in dogs. Biopure has sold more than 200,000 units of Oxyglobin since the product's launch.

Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that the company will be able to remain in business beyond the near future or achieve the minimum bid price of $1 to avoid delisting from Nasdaq. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the products' commercial use, whether or not product related, and the other factors identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q filed on March 25, 2009, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

    Contact:   Zaf Zafirelis
               Biopure Corporation
               (617) 234-6500
               IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biopure Exploring Strategic Options
2. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
3. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
4. Biopure Sues National Institutes of Health Official
5. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
6. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
7. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
8. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
9. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
10. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. Biopure Announces Closing of $14.9 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the official ... Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony on ... of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than 1,400 ...
(Date:3/28/2017)... ... 2017 , ... For many women, getting birth control isn’t as easy as it should be. ... have access to a health care facility or a pharmacy within 60 minutes of where ... States or for many who are faced with health or personal issues that leave them ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth ... Congress to protect parental rights and civil liberties, and to restore transparency within ... The demonstration coincides with a press conference taking place Friday morning calling on ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., a ... announce it has joined the National Association for Home Care and Hospice (NAHC), ... disabled, and dying Americans of all ages and the caregiver who provide them ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a ... Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip ... in association with efforts by the American College of Surgeons, U.S. Department of ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... FREMONT, Calif. , March 29, 2017 /PRNewswire/ ... vision for patients as the highest standard in ... Today, Krypton Vision introduces its objective Wavefront-driven refraction ... conventional, subjective approach. This enables an unprecedented level ... optics - exceptional vision relegated to Topgun Navy ...
(Date:3/29/2017)... , March 29, 2017 According to a new ... Type (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, ... 2021" published by MarketsandMarkets, the market is expected to reach USD 1,215.4 ... of 6.5% from 2016 to 2021. Continue ... ...
(Date:3/29/2017)... 2017  Maxor National Pharmacy Services, LLC ("Maxor"), a ... named Leah Bailey as General Counsel.  Bailey will ... company. With more than 13 years of ... focused on health care, Bailey joins the Maxor team ... Bailey advised the PBM, Specialty, and Mail Order business ...
Breaking Medicine Technology: